Jaguar Animal Health, Inc. (NASDAQ:JAGX) Sees Large Increase in Short Interest

Jaguar Animal Health, Inc. (NASDAQ:JAGX) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totaling 599,897 shares, a growth of 24.7% from the March 31st total of 481,255 shares. Based on an average daily volume of 686,294 shares, the days-to-cover ratio is currently 0.9 days. Currently, 4.7% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on JAGX shares. Wall Street Zen lowered Jaguar Animal Health to a “strong sell” rating in a research note on Friday, January 23rd. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $2,100.00.

Jaguar Animal Health Trading Down 3.9%

NASDAQ JAGX traded down $0.27 on Friday, reaching $6.69. 61,906 shares of the company were exchanged, compared to its average volume of 19,537. The business’s fifty day moving average price is $16.45 and its 200 day moving average price is $34.15. The stock has a market capitalization of $2.48 million, a P/E ratio of -0.20 and a beta of 0.02. The company has a current ratio of 0.50, a quick ratio of 0.29 and a debt-to-equity ratio of 4.08. Jaguar Animal Health has a fifty-two week low of $6.63 and a fifty-two week high of $462.00.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.